Abstract #1074

Six month clinical outcomes following pulmonary contrast enhanced magnetic resonance angiography for the primary workup of pulmonary embolism

Mark L. Schiebler¹, Michael D. Repplinger², Christopher Lindholm³, John Harringa², Christopher J. François¹, Karl K. Vigen¹, Azita G. Hamedani², Thomas M. Grist^1,4,5, Scott B. Reeder^1,2,4,6, and Scott K. Nagle^1,5,7

¹Radiology, UW-Madison, Madison, WI, United States, ²Emergency Medicine, UW-Madison, Madison, WI, United States, ³UW Madison School of Medicine, UW-Madison, Madison, WI, United States, ⁴Biomedical Engineering, UW-Madison, Madison, WI, United States, ⁵Medical Physics, UW-Madison, Madison, WI, United States, ⁶Medicine, UW-Madison, Madison, WI, United States, ⁷Pediatrics, UW-Madison, Madison, WI, United States

The aim of this study was to determine the effectiveness of pulmonary magnetic resonance angiography (PE-MRA) for the primary diagnosis of pulmonary embolism (PE). We retrospectively reviewed the electronic medical records of 675 consecutive patients who underwent PE-MRA. Adverse events (venous thromboembolism (VTE), bleeding or death) that were potentially related either to over or under treatment of PE during the subsequent 6 months were extracted from the electronic medical record. The negative predictive value for this test was found to be 97%. Based upon these outcomes, PE-MRA performs similarly to CTA as a primary test to exclude clinically significant pulmonary embolism in patients presenting acutely with dyspnea.

This abstract and the presentation materials are available to members only; a login is required.

Join Here